Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

 
• By Joseph Haas
Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications

More from New Products

More from Scrip